Difference between revisions of "Pixantrone (Pixuvri)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "analogue" to "analog") |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=269678 NCI Drug Dictionary]: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=269678 NCI Drug Dictionary]: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analog with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. |
Route: IV | Route: IV | ||
| Line 8: | Line 8: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2012-05-10: Initial authorization as Pixuvri | *2012-05-10: Initial authorization as Pixuvri | ||
| − | *Uncertain date: Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory | + | *Uncertain date: Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory [[:Category:Aggressive non-Hodgkin lymphomas|aggressive non-Hodgkin B-cell lymphomas (NHL)]]. The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy. |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' BBR 2778 | + | *'''Code name:''' BBR-2778 |
*'''Generic name:''' pixantrone dimaleate | *'''Generic name:''' pixantrone dimaleate | ||
*'''Brand name:''' Pixuvri | *'''Brand name:''' Pixuvri | ||
| Line 17: | Line 17: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:EMA approved in 2012]] | [[Category:EMA approved in 2012]] | ||
Latest revision as of 13:51, 23 September 2023
Mechanism of action
From the NCI Drug Dictionary: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analog with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. Route: IV
Diseases for which it is used
History of changes in EMA indication
- 2012-05-10: Initial authorization as Pixuvri
- Uncertain date: Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
Also known as
- Code name: BBR-2778
- Generic name: pixantrone dimaleate
- Brand name: Pixuvri